CATIE news story
A team of researchers in several countries participated in a review of clinical trials of Maviret for the treatment of chronic HCV infection. The researchers were interested in the safety and tolerability of Maviret in people who had chronic health conditions in addition to chronic HCV. They were also interested in finding out how people who were taking multiple medications for these other chronic health conditions tolerated Maviret.
In an analysis of 6,547 participants in 21 clinical trials, the researchers found that despite many participants having co-existing conditions (comorbidities), overall Maviret was highly effective and well tolerated, with relatively few people discontinuing this treatment. What’s more, the researchers stated that “potential drug-drug interactions between [Maviret and a range of the following medicines should not be a barrier to initiating HCV treatment]:
- antipsychotics
- calcium channel blockers (a group of medicines used to treat high blood pressure and irregular heart rhythms)
- beta blockers (a group of medicines used to treat abnormal heart rhythms and anxiety)
- other medicines used to treat high blood pressure
- drugs to lower cholesterol levels
- opioids
Read the full news story here.
Source : CATIE
Related HIV and Co-Infections News
-
CATIE: Spanish study finds similarly low rate of new cancers after liver transplantation in people with and without HIV
-
aidsmap: Kaposi sarcoma claims lives of South Africans with HIV, despite the ART rollout
-
Infectious Disease Special Edition: People living with HIV have comparable long-term outcomes after modern liver transplantation
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.